Persistence, Clinical and Economic Impact of Infliximab CT-P13 in Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Naïve and Switched Patients: After 5 Years of Follow-Up

Abstract

Objective: Study the economic impact and persistence of Inflectra® in rheumatoid arthritis (RA), psoriatic arthropathy (PSA), psoriasis, ankylosing spondylitis (AS) naïve, and Remicade® switched patients. Methods: Retrospective observational cohort study of patients treated with Inflectra® for more than six months in a five years analysis. We collected age, sex, indication, dose, and persistence (in years) for Inflectra® naïve and Remicade® switched patients. Efficacy endpoints included a disease activity score calculator for rheumatoid arthritis (DAS28) and bath ankylosing spondylitis disease activity index (BASDAI). Safety was also assessed. We determined each patient's actual cost of Inflectra® treatment from individualized IV administration and correlated dates during the study period. We simulated the actual cost of these patients if the patients received Remicade®. Results: During five years, 62 patients (38 women; 31 AS, 18 RA, 13 PSA were treated with Inflectra®. 33 (53%) patients were naïve patients, and 29 (47%) were Remicade® switched patients. In Sept 2019, 33 patients continued on Inflectra® treatment (11 naïve; 22 Remicade® switched) in clinical remission. Twenty-nine patients discontinued therapy, 24 due to relapse, and five due to adverse reactions. All patients with Inflectra® presented a persistence of 24.4±7.4 months. The persistence in naïve patients was 19.1±4.4 months and in Remicade® switched patients was 29.7±5.8 months. The total associated costs of the Inflectra® treatment throughout the observation period were 901.840€. If these patients had been treated with Remicade®, the total cost of therapy would have been 1.099.803€. The use of Inflectra® saved 197,964€ during five years. Conclusions: Inflectra® produces similar persistence and substantial cost savings when used in Infliximab naïve patients and Remicade® switched patients.